The researchers developed a qPCR test that analyzes microRNAs associated with ovarian cancer and plan to run a retrospective trial of the assay on biobanked samples.
Using multiple samples from more than 60,000 individuals at a participating hospital, the firm tracks circulating molecules over time in relation to cancer.
Researchers in the US and Ukraine built a microRNA-based classifier to categorize infants as affected or unaffected.
Researchers from Northwestern University uncovered five circulating microRNAs that differentiate patients with very high- and low-risk prostate cancer.
The company sees microRNAs as the ideal blood-based biomarker for diagnosing and monitoring a number of diseases at the point of care and in the developing world.
UK researchers have technically validated a qPCR testing method for a panel of four microRNAs with high sensitivity in diagnosing and monitoring rare tumors.
The company provided updates on its pipeline of NGS cancer assays, including plans to launch a lung cancer fusion panel by the end of this year.
The team recently received funding to develop and validate an assay to help guide clinical decision making when pancreatic cancer precursor lesions are detected.
Unlike past efforts by other groups, the study will include individuals with polyps that give rise to colorectal cancer, not just cancer patients.
The company is developing a prototype system that it aims to later validate in clinical samples.
The New York City medical examiner is overseeing an effort to identify missing persons using DNA, according to the Associated Press.
Nobel laureate Günter Blobel has died at 81, the New York Times reports.
In PNAS this week: mouse model of genetically induced emphysema, gene expression signatures of circulating melanoma cells, and more.
Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.